Wetteny Joseph: Thanks, John. I will start by providing an update on changes we have made related to our reporting segment structure. Slide 7 shows both the view of our former reporting structure, as well as what the revised structure looks like.  In light of the Bloomington Biologics deal, we reorganized our business to better align our internal business unit structure with our Biologics strategy. Under the revised structure, which parallels and reflects how we manage our business internally, we have split our Drug Delivery Solutions operating segment into two segments, Biologics and Specialty Drug Delivery, and Oral Drug Delivery. Our Biologics and Specialty Drug Delivery segment encompasses manufacturing, developments of Biologic cell-lines blow-fill-seal unit-doses, prefilled syringes, vials, cartridges and other injectable and inhaled formats; analytical development and testing services for large molecules; and development and manufacturing for inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays.  Our Oral Drug Delivery segment, includes comprehensive formulation manufacturing and analytical development capabilities using advanced processing technologies such as bioavailability enhancement, controlled release, particle size engineering; and taste-masking for solid oral dose forms. There is no change to our Softgel Technologies or Clinical Supply Services segments.  Therefore, for financial reporting purposes, we present four segments, Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services.  Next, please turn to Slide 8 for a more detailed discussion on segment performance beginning with our Softgel business. As in past earnings calls, my commentary around segment growth will be in constant currency.  Softgel revenue of $241 million declined 7% during the quarter with segment EBITDA declining 8% due to lower high margin product participation revenue and lower consumer health and prescription volumes in North America and Europe, partly due to the shortage of Ibuprofen and active pharmaceutical ingredient as discussed on our last few earnings calls.  Our Canadian Softgel business acquired as part of the Accucaps deal during the third quarter of the prior fiscal year continued to perform well and realized strong EBITDA growth in the quarter driven by favorable product mix and operational efficiencies at the sites.  Additionally, we experienced higher demand for consumer health products in Latin America and favorable product mix in Asia-Pacific post the divestiture of lower margin businesses in Australia and China. While these growth drivers were not large enough to overcome the headwinds related to product participation and the Ibuprofen shortage.  Going into fiscal year 2019, we expect the Ibuprofen shortage to continue for the first half of the fiscal year and the product participation headwinds to continue through the first quarter of the fiscal year. As a result, we expect Softgel revenues to grow at the lower end of the segment’s historical annual revenue growth rate during fiscal year 2019 as John mentioned earlier.  Slide 9 shows that our newly created Biologics and Specialty Delivery segments reported revenue of $195.5 million in the quarter, which is up 98% versus the comparable prior year period with segment EBITDA growing 151% during the quarter.  A sizable portion of the segment’s revenue and EBITDA growth was driven by Bloomington Biologics acquisition, which closed in October of 2017 contributed 71 percentage points to the revenue growth and 115 percentage points to the EBITDA growth. The Bloomington site continues its fast forward and we feel good about the immediate and long-term growth prospects of this business. 
Wetteny Joseph: Yes, it has. So first of all, with respect to Oral Drug Delivery last – prior fiscal year Q4, we didn’t detail out – detailed the specific impact of the contract settlement. What I would say was most of the driver in this year in respect to looking at the comps for fourth quarter versus the prior year, particularly from an EBITDA line perspective.  The other element I would remind you on as well is, we have – we included in our guidance for FY 2018 the product participation impacts, particularly given the higher margin impact of those, for the segment and those came in right in line with our expectations and have now lapped those with the fourth quarter and don’t expect those at least for the Oral Delivery segment to continue into FY 2019. 
Wetteny Joseph: On the guidance question, what I would say is, we have two acquisitions that we’ve put into the bridge for clarity and transparency here. We have not broken out separately down for the site level, these are two individual sites acquisitions. But you can clearly see what the contribution is in terms of the inorganic element into our fiscal year.  I’ll start with respect to Softgel and then I’ll let John chime in on that in terms of the business. I think John mentioned, this is a business when we look at it historically have grown in that 2% to 4% range for a long period of time and now we are seeing it’s going at the low-end of that and our confidence in terms of the asset have growth as we are looking at the pipeline of products that we have, we talked about development revenues from NPIs and number of NPIs that we launched in 2018, we are continuing to see a pretty robust pipeline of products to advance for a good subset of those NPIs.  They are targeting patient population for the smaller, in some cases orphan indications and so on. So the business continues to really perform well on attracting its share of new products which is those products that are going after a larger population. So, we still the business well positioned competitively for growth.
Wetteny Joseph: Yes, so, one, first of all, we provide guidance at the total Catalent level. We don’t break it down to the individual reporting segments within that. Obviously, we take all of those inputs into consideration in coming up with our long-term guidance which is organic growth rate of 4% to 6%. Obviously, inorganic acquisitions will be additive to those. So, we continue to drive it that way in terms of overall Catalent and not down to the individual business units. 
Wetteny Joseph: So, first of all, I would say that, we are going to continue to spend CapEx in about the 7% of company revenues for this year and going forward. However, there is going to be a disproportionate amount of that CapEx is going to be applied towards our faster growing higher margin businesses.  Certainly, Biologics, and I’ve already talked about the fact that we are contemplating fourth and fifth trains for Madison. So, that’s all baked into the current estimated guidance. 
Wetteny Joseph: So, when you look at the 160 basis points we’ve included in our guidance of fiscal year 2019, Ricky, I would say half relates to the following. A mix shift towards more Biologics with the addition of the Bloomington, as well as our organic Biologics assets rolling and outpacing the input utilization of our capacity, as well as the operational execution areas that we mentioned, particularly within the Softgel business.  So, those are roughly half of the 160 basis points with the other half contribution coming in from the moving the low-margin comparator revenue and reporting that on a net basis starting in fiscal year 2019, given the change to ASC 606. So that’s half and half. 
Wetteny Joseph: Ricky, we really haven’t disclosed margin goals down to the individual segment level, simply to say that our goal and our target which we’ve been saying was to deliver anywhere from 300 to 400 basis points extension in the next three to four years now with FY 2019 guidance we are essentially one year into that and delivering 160 basis points.  So, as John just mentioned, we’ll have another 200 to 300 basis points to deliver in the next few years. So that’s the context we like to look at margin expansion and the only other thing I would say is, if you look historically, you’ll see that the Softgel business has historically been very consistent in terms of its delivery of EBITDA margins and now we are looking at these improvements to continue to outpace the business and maybe even better than it has going forward. 
Wetteny Joseph: The way I would think about it is, as we look ahead, we will continue to see growth in our Biologics and that representing a bigger share of the overall Catalent pie. We ended FY 2017 with Biologics representing about 14%, now it’s 26%. We still have another quarter of the Bloomington acquisition and our organic business, plus Bloomington will continue to grow.  We’ve talked about the third train in Madison considering now a fourth and fifth train in Madison. Again, that’s all going towards a mix shift for overall Catalent. It’s going to continue to drive margin expansion for the overall business in addition to our operational execution, where on a business like Softgel that is growing at the lower end of its historical rates, we see an opportunity to balance that with a focus on our operational perspective, Centers of Excellence around the world that will drive more throughputs for the business.  So, those are the elements that I would say are going to drive this expansion. If you start at where we ended sort of FY 2018 and you put another 300 to 400 basis points to bracket that over a period of three to four years, FY 2019 clearly is a nice step towards that is how the framework I would give you. 
Wetteny Joseph: So, Sean, this is Wetteny here. We really haven’t specifically quantified that in terms of the fourth quarter of FY 2017. But what I would say, when we look at the fourth quarter of FY2018, the majority of the comparison to the prior year is driven by that contractual settlement at the EBITDA line for sure.  And then, the other contribution which we’ve been talking about now all year and it was well in line within our expectations was the impact of foreign participation which is also high margin opportunities that are towards the end of their lifecycles and we have now completed last of those for the Drug Delivery segment. It won’t be part of the top shack as we look forward for that segment. So those are two elements drove the vast majority of the comparable year-over-year. 
Wetteny Joseph: If you are looking at 2% maybe an annual number on that, I would say that, we haven’t put a specific number to it, 2% sounds low if you are looking just the quarter. And, again, we didn’t quantify that in terms of what the impact was in terms of dollars. 
Wetteny Joseph: Well, 3.5 continues to be our long-term target, as John mentioned, we first and foremost look for organic growth opportunities in investing in our fast-growing parts of the business and then we look for strategic acquisitions given where we are right now, our balance sheet and our leverage ratio, we continue to have a good solid pipeline of potential targets.  But again, those only become actionable from time-to-time and we are now trying to be able to execute should one of those become actionable for us. The 3.5 times remains our long-term target. 
John Chiminski: So, I think, the biggest part of this is that, we have seen a historical growth rate for this segment in the 2% to 4% range and we can build back over a seven to ten year period and there was only a short period there where we really went after BMS business in the Asia market to soak up some unutilized capacity and as we – I would say, retooled our strategic plans to really focus on higher growth and higher margin businesses, we essentially took a step back I would say from some of that BMS business.  As you know, we’ve divested two assets in Asia that were Softgel. We also had headwinds both in our fiscal year 2018 which we didn’t detail out in great – to great extent but we’ve had headwinds that were from the Ibuprofen shortage and those headwinds are going to continue into our FY 2019, certainly through the first half.  You already mentioned the fact that we are now lapping Accucaps and quite frankly, the funnel that we have for new product introductions for Softgel is really for much smaller disease states, smaller disease populations. So as we kind of netted all these things out, we really have moved strategically into a mode where Softgel has been a great cash flow generator at very high ROIC for the company.  And what we’ve really done is moved into a mode where we are going to continue to lean on a cash flow generation of the Softgel business on a go-forward basis to really continue to fund our growth in the higher growth, higher margin businesses of Biologics. We are going to be driving margin expansion much more aggressively within this segment.  So you can see from our overall estimates that we had EBITDA coming in actually quite nicely although the revenue is more or less flat. So, what I would say is that, from a strategic standpoint, we’ve really moved this business into its historical growth rate and are really focusing on its cash contribution and its margin expansion as the primary points of the asset for the business. 
John Chiminski: Yes, the only thing I would add is, we do have very strong development revenues that are coming out of the business. We see that increasing – we’ve seen increasing number of NPIs and quite frankly, while although we have the prescription part of the business going towards smaller more focused disease case, the consumer health part of the business continues to be very robust.  We have a very strong pipeline of both owned products as well as just products that our customers are coming to us with and certainly Accucaps significantly strengthened that. So, I think, even as in the near term we would see the business growing at the low-end of that overall historical growth rates, the long-term prospects for the business continue to be strong. 
John Chiminski: No, I would just tell you that, first of all, the overall space continues to be very robust. So we continue to have a significant number of new molecules that are coming into this space. I think the overall trend is towards more focused disease states, orphan drugs and so forth. That being said, there continue to still be significant unmet needs in some of the larger spaces, whether they be in C&Fs and so forth.  I would really say that, we just see an industry pipeline that continues to grow. So it doesn’t mean that there are blockbusters or molecules that are going to be attacking the significant unmet needs. But the net of it at this point is we are seeing a much more focus towards some of the smaller more focused disease states.  But we got a great pipeline in the Oral Drug Delivery segment. They continue to win a substantial number of new programs and it will be a growth segment for us. So the other ones was really only Softgel being one that we are pointing out that we believe is going to continue to grow at that historical growth rates of 2% to 4% with the near-term being at 2%. 
John Chiminski: Yes. No, we are completely through that issue and we had to work through some early start-up issues. It was a small design and a manifold something I need to detail out here. But we are well beyond that and then as we go into our fiscal year 2019, we expect to based on the very strong demand, we should probably get 50% or more capacity utilization out of that third train.  And as I also mentioned in my notes, we are already contemplating the fourth and fifth train for Madison. So, it continues to be an extremely robust area for the company. 
John Chiminski: We see the business operating just over 50% capacity utilization now coming out of fiscal year 2018. I think John mentioned in his comments, prepared comments as well, that we continue to see more products being approved commercially for the site. At the time of the acquisition, we had 12 products approved.  Now the number is 17. So we continue to be – to look forward to continued growth in utilization of capacity at the site where we estimated previously around 40%. Now we are seeing just over 50%. 
John Chiminski: What I would just add from a free cash flow perspective, you’ve seen in the last two years, we’ve generated over 85% of adjusted net income and free cash flow that’s after CapEx. Obviously, we continue to guide to somewhere between 65% and 75% of our A&I through free cash flow and as we look at our CapEx, it does lean towards the higher growth portions of our business.  Certainly, in the Biologic assets, our Bloomington and our pre-existing businesses will see a lion share of that where we also have maintenance CapEx obviously in a highly regulated industry that we are in to continue to drive that. So we keep pegging the number around 7% or so of our top-line with the 50% of that being growth-oriented and of that growth-oriented more of it’s leaning towards the biologics assets obviously. 
John Chiminski: Yes, so John here. I would say, first of all, we had obviously, the successful equity raise and now basically about our debt, our ratio is down to a point where we consider ourselves having significant dry powder if you will for continued bolt-on acquisitions and potentially something more meaningful in some adjacent white spaces.  In addition, in the near-term, we certainly, in a rising interest rate environment have also – have eliminated about $20 million of interest payments through the term loan pay down. So, I would say for us, this was really much more of a strategic move for us and it was, I would say clearly financial, strategic from a standpoint that we wanted to have the balance sheet flexibility to be able to continue to pursue our strategic plans.  And certainly we are an organic growth company. But we use acquisitions to really accelerate our strategic plans and with our balance sheet where it is now and it just gives us that much more flexibility and ability to act.
John Chiminski: Ricky, I would also – sorry, I would also just add that we are still looking at another 200 to 300 basis points of margin expansion opportunity over in the next several years that we are managing in addition to the 160 that’s been baked into our FY 2019 guidance. 
John Chiminski: I don’t know that we’ve disclosed specific number of products. What I would say is, the pipeline continues to be robust. We – one of the attraction in making the acquisition is running around a 100 molecules sort of in development really the track record or if you look at the overall industry, you would say, the track records coming out of this acquisition in terms of number of pipes that have gone commercial.  They were at 12 at the time of the acquisition, just in October and now just a few short quarters later, we are talking about 17. So, clearly the site has a real track record and a pipeline that has advanced and continues to advance. So we remain very optimistic in terms of the future in terms of what we will see over the next couple of years coming out of the pipeline. 
John Chiminski: So, there is nothing about working with train. It’s in our current guidance and I would just say that, given the fact that we are already going to be using our third train upwards of 50% this year that clearly that’s already getting us to a point where we know need to move forward to add additional capacity. So there is still work to be done.  We just have this in engineering design phase right now, but highly confident that a fourth and fifth train will be needed given the fact that the third train just completed for its first year will already be at 50%. So, I think the very strong growth momentum that we have both in Bloomington and Madison is going to continue given where the industry is going with Biologics. 
John Chiminski: Thanks, operator and thanks everyone for your questions and taking the time to join our call. I’d like to close by reminding you of a few important points. First, we are confident in and committed to delivering fiscal year 2019 results consistent with our financial guidance and are focused on continuing to drive organic growth across our overall business.  Second, we are committed to building a world-class Biologics business for our customers and for patients and look forward to continued strong revenue and EBITDA growth from our Biologics offerings. Third, the continued successful and efficient integration of Bloomington Biologics as well as the integration of the Juniper Pharmaceuticals business into the Catalent family, our top priority as we look to swiftly capitalize on our recent inorganic investments.  Next, expanding the EBITDA margin of our business is a key focus area for the management team as we drive towards 200 to 300 basis points of further expansion over the next three to four years. Last but not least, operations, quality, and regulatory excellence are at the heart of how we run our business and remain a constant focus and priority.  We support every customer project with deep scientific expertise and a commitment to putting the Patient First in all we do. Thank you.
